Abstract | PURPOSE: METHODS: We conducted a cohort study using a representative 1/97th sample of the French healthcare insurance database between 2014 and 2019. Patients with AF receiving apixaban or rivaroxaban were included and followed-up until hospitalization for bleeding, death, discontinuation of apixaban or rivaroxaban, exposure to strong CYP3A4 inhibitor, or until December 31st 2019, whichever came first. Primary outcome was hospitalization for bleeding registered as primary diagnosis. The association between the exposure to the DDA and hospitalization for bleeding was evaluated as a time-dependent variable in Cox model. RESULTS: Between 2014 and 2019, the AF population under apixaban or rivaroxaban represented 10,392 patients. During the study period, the annual average prevalence of DDA exposure in this population was 38.9%. Among the 10,392 patients, 223 (2.1%) were hospitalized for bleeding, of which 75 (33.6%) received the association and 148 (66.4%) received apixaban or rivaroxaban alone. There was no association between DDA exposure and risk of hospitalization for bleeding (aHR = 1.19, [95% CI: 0.90, 1.58]). Age (HR 1.03 [1.02, 1.05]) and male gender (HR 1.72 [1.28, 2.30]) were associated with an increased risk of hospitalization for bleeding. CONCLUSION:
|
Authors | Laëtitia Gosselin, Ana-Maria Vilcu, Cécile Souty, Olivier Steichen, Titouan Launay, Cécile Conte, Béatrice Saint-Salvi, Clément Turbelin, Marianne Sarazin, Thierry Blanchon, Thomas Hanslik, Maryse Lapeyre-Mestre, Louise Rossignol |
Journal | European journal of clinical pharmacology
(Eur J Clin Pharmacol)
Vol. 79
Issue 7
Pg. 937-945
(Jul 2023)
ISSN: 1432-1041 [Electronic] Germany |
PMID | 37184597
(Publication Type: Journal Article)
|
Copyright | © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. |
Chemical References |
- Rivaroxaban
- Anticoagulants
- Anti-Arrhythmia Agents
- Pyridones
- Dabigatran
|
Topics |
- Humans
- Male
- Atrial Fibrillation
(drug therapy, epidemiology)
- Rivaroxaban
(adverse effects)
- Anticoagulants
(adverse effects)
- Anti-Arrhythmia Agents
(adverse effects)
- Cohort Studies
- Prevalence
- Hemorrhage
(chemically induced, epidemiology)
- Pyridones
(adverse effects)
- Delivery of Health Care
- Dabigatran
(adverse effects)
- Stroke
(epidemiology)
|